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INTRODUCTION 
 
 Aspirin is one of the most widely used drug as a anti-platelet agent. 
Low dose aspirin is the one among the important drugs to be used in 
management of acute coronary syndrome, acute ischemic stroke. Low dose 
aspirin has to be taken for life time as a secondary prophylactic measures in 
coronary artery heart disease, ischemic stroke patients. Currently more than 
300 proprietary preparations contain aspirin and the annual consumption is in 
excess of 20 billion tablets. 
 Aspirin is most widely studied antiplatelet agent. Its antiplatelet effect is 
accomplished by acetylating cyclooxygenase enzyme in platelets, thus results 
in direct inhibition of prostaglandins and thromboxanes from arachidonic acid. 
This effect is permanent and lasts for the usual 8 day life time of the platelets. 
Aspirin in doses of 160-325mg daily inhibits the production of thromboxanes 
A2 in platelets without substantially inhibiting prostacycline formation. 
 Aspirin is absorbed into gastric mucosal cells where it becomes ionized 
because of the higher intra cellular pH and damages the cell. The gastro 
intestinal adverse effects of aspirin are well known for many decades. Aspirin 
produces dose related GI toxicity. The spectrum of GI morbidity due to aspirin 
therapy ranges from minor symptoms like nausea, anorexia, to a serious 
gastro intestinal complications such as peptic ulceration, GI hemorrhage, 
perforation. Inspite of this, it is widely used, because the benefits out weigh 
the risks and it is a cheaper drug. Non acetylated salicylates appear to cause 
a lower incidence of gastro duodenal ulceration than does of aspirin. 
  
Even though there are lot of studies about the gastro duodenal 
mucosal changes in patients on larger dose aspirin, there are only few studies 
with low dose aspirin therapy. So we decided to do an endoscopic study in 
patients on long term low dose aspirin therapy.    
  
AIM OF STUDY 
 
1. To document various types of gastro-duodenal changes of patients on 
low-dose aspirin therapy endoscopically. 
 
2. To correlate dyspeptic symptoms with endoscopic findings. 
 
3. To know the gastrointestinal safety of low dose aspirin on long term 
treatment. 
 
 REVIEW OF LITERATURE 
 
2.1.1) History of Aspirin 1: 
 The use of willow bark and leaves to relieve fever has been attributed 
to Hippocrates, but was most clearly documented by Rev. Edmund Stone in 
1763. Similar properties were attributed to portions from meadow sweet 
(Spiraea ulmaria), from which the name aspirin is derived. 
 Salicin was crystallized in 1829 by Leroux and Pina isolated salicylic 
acid in 1836. In 1859 Kosbe synthesized salicylic acid and by 1874 it was 
being produced industrially. 
 In 1899, Hoffman sought to improve the adverse effects profile of 
salicylic acid. Bayer laboratories in 1899 began testing in animals, the first 
time that a drug was tested on animals in an industrial setting and proceeded 
to human studies and the marketing of aspirin. In 1971 Vane discovered that 
aspirin inhibits PG synthesis and induces GI injury. 
 
2.1.2) Mechanism of action of aspirin 1: 
 The principal therapeutic effects of aspirin is inhibition of prostaglandin 
production. The first enzyme in the prostaglandin pathway is cyclooxygenase. 
This enzyme converts arachidonic acid (AA) to unstable intermediates PG G2 
and PG H2 and leads to the production of thromboxane A2 and other 
prostaglandins.   
  
There are 2 forms of cyclooxygenase (COX), cyclooxygenase- 1 (COX-
1) and COX-2. COX-1 is constitutively found in most normal cells, while 
cytokines and inflammatory mediators induce COX-2 production (Seibert et 
al.1997)2. COX2 also is constitutively expressed in certain areas of kidney and 
brain (Breder et al.1995)3. and is induced in endothelial cells by laminar shear 
forces (Topper et al 1996)4. Importantly COX-1 is expressed as the dominant, 
constitutive isoform in gastric epithelial cells and is the major source of cyto 
protective prostaglandin formation. 
(i) Aspirin covalently modifies COX-1 and COX-2, irreversibly inhibiting 
cyclooxygenase activity. 
(ii) This is an important distinction from all NSAIDs because the duration of 
aspirin’s effects is related to the turn over rate of COX in different target 
tissues 
(iii) The importance of enzyme turn over is most notable in platelets, which 
being anucleate, have a markedly limited capacity for protein synthesis. 
Thus platelet COX-1 inhibition last for life time of the platelet (3-7 
days). 
(iv) COXs are configured such that the active site is accessed by the 
arachidonic acid substrate via a hydrophobic channel. Aspirin 
acetylates serine 530 of COX-1, located high up in the hydrophobic 
channel. Interposition of bulky acetyl residue prevents the binding of 
arachidonic acid to the active site of the enzyme and thus impedes the 
ability of the enzyme to make prostaglandins. Aspirin acetylates a 
homologous serine at position 516 in COX-2. 
           Although covalent modification of COX-2 by aspirin also blocks the 
cyclooxygenase activity this isoform, an interesting property not shared by 
COX-1 is that synthesizes 15(R)- hydroxyl eicosatetraenoic acid, which is 
metabolized to 15-epilipoxin A4, which has potent anti-inflammatory 
properties (Serhan and Oliw 2001)5. Due to these features, repeated doses of 
aspirin that actively do not completely inhibit platelet COX-1 derived 
thromboxane-A2 can exert a cumulative effect with complete blockade. 
 
2.1.3) EFFECTS ON PLATELETS 6: 
 In blood platelets COX enzyme inhibition prevents the synthesis of 
thromboxane A2, a compound which is a vasoconstrictor, causes platelet 
aggregation and is thus potentially thrombotic. 
 In blood vessel walls the enzyme inhibition prevents synthesis of 
prostacyclin, which is a vasodilator, has anti-aggregating properties and is 
thus potentially thrombotic. Thus aspirin has paradoxical effects. 
 Duration of these effects however may differ with effects on vascular 
tissue is shorter than effects on platelets. The difference explained by the 
vascular cells regain the ability to regenerate prostacyclin in a few hours, but 
platelets are unable to resynthesise COX. 
 Inhibition is cumulative on repeated dosage and it has been estimated 
that daily doses of 20-50mg will result in complete suppression of platelet 
thromboxane within few days. Large doses of 150 to 300mg can produce 
maximal suppression almost instaneously. 
 The unique sensitivity of platelets to inhibition by low doses of aspirin is 
related to their presystemic inhibition in the portal circulation before aspirin is 
deacetylated to salicylate on first pass through liver (Pederson and Fitz 
Gerald 1984)7. 
 
2.1.4) PHARMCOKINETICS AND PHARMACODYNAMICS1,8,6: 
 Aspirin absorbed rapidly from the gastro intestinal tract when taken 
orally. Aspirin also be absorbed through skin. After oral dose, absorption of 
non-ionised aspirin occurs in stomach and intestine. 
  
Peak plasma aspirin concentrations attained within 15-40 minutes 
following oral administration as aqueous solution or uncoated tablets. Peak 
plasma salicylate concentrations attained within 30-60 minutes (or) 1.5-2 hrs 
following administrations of single 650 mg dose as an aqueous solution or as 
two 325mg uncoated tablets respectively. 
  
After absorption, aspirin is rapidly converted to salicylate. Aspirin 
begins to acetylate platelets within minutes of reaching presystemic 
circulation. Aspirin is 80 to 90% protein bound, and undergo hepatic 
metabolism. At low doses (325mg), elimination is a first order process and 
serum half life is 3.5hrs. At high aspirin doses the half life increases to 15 to 
30 hours because of saturation of hepatic enzymes and zero order kinetics. 
 
2.1.5) THERAPEUTIC USES OF LOW DOSE ASPIRIN9: 
1. Acute myocardial infarction -160-325mg- as soon as AMI suspected. 
2. Unstable angina -75-325mg initially to be given. 
3. Angina pectoris- 75-325mg once daily to be continued indefinitely. 
4. Chronic stable CAD -75- 162mg daily to be continued indefinitely. 
5. Secondary prevention in post-MI/ACS patients -75-325mg OD for life 
long.  
6. Acute ischemic stroke- 160-325 mg initiated within 48hrs of stroke.  
7. Secondary prevention of ischemic stroke -50- 325mg daily for life long. 
8. Coronary revascularization procedure – CABG, PCI -75-325mg for life 
long. 
9. Atrial fibrillation/ flutter- 150-325mg those with persistent or paroxysmal 
AF at high risk of stroke. 
10. MVPS with unexplained TIAs -50-162mg daily. 
11. Carotid end arterectomy -75-162mg initiated pre-operatively and 
continued    indefinitely. 
12. Chronic limb ischemia -75-325mg continue indefinitely. 
13. Prolonging patency of vascular grafts  -75-325mg 
14. Acute pericarditis -160-325mg 
15. Bioprosthetic heart valves- long term in those in sinus rhythm. -75-
100mg. 
 
2.1.6) ADVERSE EFFECTS10: 
• Gastro intestinal system: Abdominal pain, nausea, anorexia, gastric 
erosion/ulcers, anemia, GI hemorrhage, perforation, diarrhea. 
• Renal: salt and water retention, edema, worsening of renal function, 
in renal/cardiac and cirrhotic patients, decreased effect of anti 
hypertensive medications, decreased urate excretion. 
• CNS: headache, vertigo, dizziness, confusion, depression, 
hyperventilation. 
• Platelets: inhibited platelet activation, propensity for bruising. 
Increased risk of hemorrhage. 
• Hypersensitivity: vasomotor rhinitis, angio neurotic edema, asthma, 
utricaria, flushing, hypotension, shock. 
• Vascular closure of ductus arteriosus. 
 
2.1.7)  CAUTIONS9: 
 (A) Contraindications: 
• Known hypersensitivity to aspirin or any ingredient in the formulation. 
• History of asthma, utricaria, or other sensitivity reaction precipitated 
by other NSAIDs. 
• Syndrome of asthma, rhinitis, and nasal polyps.  
• Children or adolescents with viral infections (with or without fever) 
because of possibility with an increased risk of Reye’s syndrome. 
(B) Warnings/ Precautions: 
• Long term alcohol use associated with an increased risk of aspirin 
induced bleeding. 
• It increases bleeding time. These effects important in platelets with 
inherited (or) acquired bleeding disorder. 
• Serious GI toxicity (bleeding, ulceration, perforation) can occur with or 
without symptoms. 
• Avoid highly buffered aspirin preparations in patients with CHF, renal 
failure or other conditions in which high sodium content would be 
harmful. 
• Renal effects are interstitial nephritis, papillary necrosis, proteinuria, 
renal failure. 
• Pregnancy: use only if clearly needed. Avoid use in 3rd trimester, 
because of possible premature closure of ductus arteriosus. Avoid 1 
week prior to and during labor and delivery. 
• Hemorrhagic complications are not observed in low dose aspirin.  
 
 
2.2) ANATOMY OF STOMACH AND DUODENUM11: 
2.2.1) Anatomic relationships and divisions: 
a. Stomach: 
 The stomach, a large, distensible bag with the largest diameter of any 
part of GIT, is located in mid upper abdomen, just beneath the diaphragm. 
The size and shape vary greatly from person to person, depending upon age, 
body habitus, posture and interval since eating. Although fixed proximally to 
esophagus and distally to the duodenum, and by gastro colic and gastro 
phrenic ligaments, the stomach has great latitude in distension and motion. 
The full stomach may reach from diaphragm to the pelvic brim. 
 The stomach abuts many organs. Diaphragm superiorly, the liver and 
biliary tract to the right, the spleen to the left, and the pancreas, transverse 
colon posteriorly. The anterior surface of stomach approximates the 
abdominal wall. Stomach is separated from these organs by peritoneal lining. 
 Stomach is divided into cardia, a 1 to 2cm segment adjacent to 
esophago gastric junction, the fundus, the superior part of stomach lying 
above and slightly posterior to the rest of stomach. The body or corpus, the 
voluminary portion of stomach, below the fundus, the antrum, the distal region 
of stomach and finally, the pylorus or pyloric channel, a narrow 1-2cm channel 
that connects the stomach to duodenum. The shorter right side of stomach is 
lesser curvature, the opposite longer left side is greater curvature. An 
intrusion, about two thirds of way along the distal lesser curvature, near 
junction of body and antrum is incisura angularis. 
2.2.1) b) Duodenum: 
 The tubular, C-shaped duodenum, nestling the head of pancreas, 
starts at the pylorus and extends to the ligaments of Treitz. The duodenum 
has no mesentry and in contrast to stomach is largely retro-peritoneal and 
fixed in position. The first part of duodenum is about 5cm long. The initial 2-
3cm of first part is duodenal bulb. The lining of bulb is relatively flat. The 
second part of duodenum takes a sharp curve and descends along the head 
of pancreas for 7 to 10cm.  The common bile duct and pancreatic ducts 
together or separately enter the medial aspect of second part at 
posteromedial ampulla of vater.  The accessory pancreatic duct enters the 
duodenum approximately 2cm proximal to ampulla.  The third part passes 
from right to left across the spine, inclining upward about 5 to 8cm.  The fourth 
part of duodenum starts left of spine, ascends left wards and terminates at 
ligament of Treitz. 
 
2.2.2) Blood supply: 
 Gastric and duodenal blood supply derive from celiac artery and the 
superior mesenteric artery. A dense anastomotic network encircles the 
stomach is formed by these arteries. The left gastric artery supplies anterior 
and superior portion of stomach. The right gastric, gastro-duodenal, right 
gastro epiploic arteries which arise from hepatic artery, supplies lower right 
portion of stomach and the lower greater curvature. The short gastric and left 
gastro epiploic arteries arise from splenic artery to feed the fundus and upper 
greater curvature.   
 The distal stomach, pylorus, duodenum are supplied by the inferior 
pancreatico duodenal branch of superior mesenteric artery. 
 Venous drainage: 
 Venous drainage from the stomach and duodenum leads directly or 
indirectly to portal vein. From the stomach, the left and right gastric veins 
drain the lesser curvature, and the left and right gastro epiploic and short 
gastric veins drain greater curvature.  From duodenum, the anterior inferior 
and superior pancreatico duodenal veins drain into superior mesenteric vein. 
The posterior superior pancreatico duodenal veins drains directly into portal 
vein. 
 
2.2.3) Lymphatic drainage: 
 The pattern of lymphatic drainage of stomach is similar to that for its 
vasculature, with most lymph draining ultimately into into celiac nodes via four 
major groups. 
 In the duodenum, anterior and posterior lymphatics drain into 
pancreatico duodenal nodes and to hepatic, pancreatic nodes, then finally into 
pre aortic nodes near origin of Superior mesenteric artery. 
 
2.3 )  GASTRIC PHYSIOLOGY11: 
Gastric Secretion  
Two secretory products with the potential of producing mucosal 
damage include hydrochloric acid and pepsinogen. Basal acid secretion 
follows a circadian pattern with the lowest secretion in the morning and the 
greatest occurring at night. Cholinergic input via the vagus nerve and 
histaminergic input from locally released histamine are the main determinants 
of basal gastric acid output. The principal physiologic stimulant of increased 
acid production is food. Meal-stimulated acid secretion is typically described 
as occurring in three phases referable to the site of origin of the stimulant and 
includes the cephalic, gastric, and intestinal phase.  
The principal determinants of the cephalic phase include sight, smell, 
and taste of food, which lead to stimulation of gastric acid secretion via 
cholinergic input through the vagus nerve. Once food enters the stomach, the 
gastric phase of acid secretion is activated. Nutrients (amino acids and 
amines) directly stimulate gastrin release, which in turn increases the 
secretory response. As nutrients enter the intestine, the last phase of meal-
stimulated gastric acid secretion is initiated. The principal stimulatory factors 
during this phase include distention and proteins and their breakdown 
products. 
As is the case with most biological systems, there are a series of 
inhibitory pathways that are activated during the different phases of gastric 
secretion, which serve as a counterbalance for the secretory process.  The GI 
hormone somatostatin seems to be an important element in this inhibitory 
process.  
Extensive effort has been placed towards understanding the cell 
responsible for secreting acid. The parietal cell is found in the oxyntic gland in 
close proximity to additional cells involved in regulating acid secretion. One of 
these cells is the histamine containing enterochromaffin-like (ECL) cell. The 
ECL cells express receptors for gastrin and acetylcholine. Stimulation of the 
ECL cell by cholinergic neurons of the enteric nervous system or by the 
hormone gastrin released from antral G cells stimulates histamine release. 
The acid-secreting parietal cell contains receptors for histamine (H2 
class), gastrin, and acetylcholine.   Activation of the parietal cell H2-receptor 
by histamine stimulates adenylate cyclase, increasing intracellular cAMP 
levels. Stimulation of the cholinergic M3-receptor or the gastrin receptor 
activates the phosphoinsitide/intracellular calcium cascade.  
 
The increase in intracellular cyclic adenosine monophosphate (cAMP) 
or cytosolic calcium leads to activation of various protein kinases, which in 
turn regulate the final common acid-secreting pump on the canalicular surface 
of the cell: the H+K+ATPase.   
 
The combination of secretagogues that activate different signaling 
pathways leads to a significant increment in gastric secretion.  This enhanced 
biological response is termed potentiation. Potentiation explains why receptor 
blockade of one pathway with an antagonist diminishes acid secretion in 
response to agents that activate an alternate pathway. 
 
The H+K+ATPase is a membrane-embedded protein that leads to the 
secretion of H+.  It consists of two subunits: an alpha subunit that contains the 
active catalytic site; and a beta subunit, the function of which is not fully 
elucidated. This enzyme uses the chemical energy of ATP to transport 
protons from the cytoplasm of the parietal cell into the secretory canaliculi in 
exchange for K+.  
The pumps are located in the secretory canaliculus and in the 
nonsecreting cytoplasmic tubulovesicles. The distribution of pumps between 
these locations depends on the degree of parietal cell stimulation. The 
cytoplasmic vesicles are impermeable to K+, thus making the proton pump 
inactive in this location. In the resting state, approximately 5% of pumps are 
active and located within the canaliculi.  
 
During stimulation, tubulovesicles of the cytoplasm are rapidly 
transferred to the membrane of the secretory canaliculus, where 60% to 70% 
of the pumps are activated. After stimulation of the parietal cell ceases, the 
proton pumps return to their inactive state in the cytoplasmic vesicles.  The 
half-life of the proton pumps is estimated to be 48 hours. 
Pepsinogen, the inactive precursor of the proteolytic enzyme pepsin, is 
produced by the chief cell, which is found primarily in the gastric fundus. The 
pathogeneric importance of derangements in pepsinosen secretion in peptic 
ulcer disease remains to be established. 
 
2.4 )  GASTRO DUODENAL DEFENSE MECHANISM 11,12: 
 The gastric epithelium is under constant assault by endogenous 
noxious factors such as HCl, pepsinogen/ pepsin, and bile salts. In addition, 
exogenously substances such as medications, alcohol, bacteria, encounter 
the gastric mucosa. The mucosal defense system can be envisioned as three 
level barrier composed of pre-epithelial, epithelial and sub-epithelial elements. 
 
2.3.1) Pre-epithelial defensive factors: 
 The first line of defense is a mucus- bicarbonate layer which serves as 
a physico-chemical barrier to multiple molecules including hydrogen ions. 
Mucus is secreted by surface epithelial cells, which is stimulated by 
prostaglandins. The thickness of mucus is approximately 100µm. mucus 
contains 95% water and 5% glycoprotein and lipids. Mucus is a dynamic 
substance which is continually being secreted and degraded 13. It functions as 
non-stirred water layer impending diffusion of ions and molecules such as 
pepsin. Bicarbonate secreted by surface epithelial cells of gastro duodenal 
mucosa forms a pH gradient that maintains neutral pH at epithelial cell 
surface14. 
 
 
2.3.2) Epithelial defensive factors: 
  Surface epithelial cells provide second line of defense through 
several factors, including mucus production, epithelial cell ionic transporter 
that maintain intracellular pH, bicarbonate production and intracellular tight 
junctions. When superficial mucosa damage occurs, surface epithelial cells 
bordering the site of injury can migrate to restore the damaged area. This is 
known as restitution 15. Several growth factors including epidermal growth 
factor, transforming growth factor α, fibroblast growth factor, modulate the 
process of restitution. Regeneration, the process by which larger epithelial cell 
defeats heal, requires cellular proliferation. 
 
2.3.3) Sub-epithelial defensive factors: 
  
An elaborate micro-vascular system within gastric submucosal layer is 
the key component of sub-epithelial defense system, providing HCO3, 
adequate supply of micronutrients and oxygen while removing toxic metabolic 
by products. 
  
Prostaglandins play a central role in gastric epithelial defense, which 
regulate the release of mucosal bicarbonate and mucus, inhibit parietal cell 
secretion, and are important in maintaining mucosal blood flow and epithelial 
cell restitution.  
  
Nitric oxide (NO) is important in maintainence of gastric mucosal 
integrity. It contributes cyto protection by stimulating gastric mucus, increasing 
mucosal blood flow, and maintaining epithelial cell barrier function. 
 
 
 
MECHANISMS OF GASTRODUODENAL MUCOSAL DEFENSE 
LEVEL OF DEFENSE  MECHANISM OR EFFECT 
TABLE 2.1 
Preepithelial 
Mucus / bicarbonate barrier 
 
Mucoid cap 
 
 
Surface-active phospholipids 
 
Epithelial 
Restitution 
 
 
 
Cellular resistance 
 
Acid-base transporters 
 
 
 
Release of growth factors (e.g., polyamines), 
prostaglandins, nitric oxide 
 
Subepithelial 
Mucosal blood flow 
 
Leukocyte adhesion and extravasation 
 
Provides a modest barrier to H+ diffusion and 
other molecules 
Develops in response to mucosal injury and 
provides a juxtamucosal alkaline or neutral 
microenvironment 
Enhance hydrophobicity of cell membrane, 
increase viscosity of surface mucous layer 
and may affect cell membranes 
Prompt reconstitution of surface epithelium 
by movement of existing cells over damaged 
area; impeded by ischemia, reduced Ca2+, 
and acidosis 
Maintains electrical gradient to prevent 
epithelial cell acidification, lowered pH1 
Transport HCO3- into the pH/mucous barrier 
and subepithelial tissues (i.e., alkaline tide), 
and extrude acid to prevent cellular 
acidification 
Growth factors promote cell division; 
prostaglandins stimulate mucus and HCO3- 
secretion and increase mucosal blood flow; 
nitric oxide increases mucosal blood flow 
Delivers nutrients and buffers, especially 
HCO3-, to the surface epithelial cells 
Neutrophil endothelial adherence and their 
extravasation into the submucosal tissues 
with the release of cytokines and the 
generation of oxygen-derived free radicals 
are important factors in experimental mucosal 
injury. 
2.5 )  ABNORMALITIES ASSOCIATED WITH PEPTIC ULCER16: 
Reported abnormalities in gastric acid secretion, acid homeostasis, and 
gastro duodenal motility that are associated with peptic ulcer disease are 
reviewed in this section. Consequently, clinical investigations on peptic ulcer 
conducted before 1984 do not even consider the H. pylori status of the study 
population. Although this infection is found in more than 80% of patients with 
duodenal ulcer and in more than 60% of patients with gastric ulcer, the 
precise contribution of H. pylori to a number of the physiologic abnormalities 
described in peptic ulcer disease remains unclear. 
 
2.5.1)  ABNORMALITIES ASSOCIATED WITH DUODENAL ULCER: 
Numerous studies have concluded that patients with duodenal ulcer 
disease tend to be hyper secretors of gastric acid. Autopsy studies have 
shown that groups of duodenal ulcer patients have greater mean numbers of 
gastric parietal cells than groups of control subjects without peptic ulcers, 
although much overlap is observed between these groups The average 
maximal and peak acid outputs (which correlate with parietal cell mass) and 
the mean duration of meal-stimulated acid secretion also are greater in 
patients with duodenal ulcer than in control subjects, again with considerable 
overlap among individuals within the groups, Similarly, basal acid output, 
daytime acid output, and nocturnal acid output are, on average, increased in 
patients with duodenal ulcer compared with control subjects without peptic 
ulcer disease The abnormality in nocturnal gastric acid secretion may be 
particularly important because during sleep, when there is no food in the 
stomach to buffer gastric acid, the gastro duodenal mucosa may be especially 
susceptible to peptic injury, 
Abnormalities in the homeostatic mechanisms that regulate gastric acid 
output may contribute to the acid hypersecretion found in some patients with 
duodenal ulcer. For example, fasting serum gastrin levels are higher in 
duodenal ulcer patients than in normal control subjects. Meal- and gastrin-
releasing peptide-stimulated gastrin levels are also higher in H.pylori infected 
duodenal ulcer patients than in uninfected normal control subjects, but these 
levels in ulcer patients are no higher than those of control subjects with 
H.pylori infection who are otherwise normal. In some cases the gastrin 
abnormalities associated with duodenal ulcer are reversible with eradication of 
H. pylori infection. The precise mechanisms underlying the aberrant gastrin 
secretion found in duodenal ulcer disease are not clear but may involve H. 
pylori-induced increases in cytokines such as tumor necrosis factor-a that 
stimulate gastrin release from G cells and H.pylori mediated  decreases in the 
mucosal expression of somatostatin, a peptide that normally suppresses 
gastrin release. This decrease in mucosal somatostatin may underlie the 
impaired inhibition of acid secretion in response to antral distention and antral 
acid secretion that has been described in some patients with duodenal ulcer 
disease. 
 
Serum concentrations of pepsinogen I, a protease made by chief and 
mucous neck cells in the gastric oxyntic mucosa, are elevated in up to 50% of 
patients with duodenal ulcers.  This phenomenon may reflect the increased 
gastric secretory mass of patients who have duodenal ulcers. Although once 
regarded as a genetic marker for duodenal ulcer disease, 
hyperpepsinogenemia appears to be another reversible consequence of 
H.pylori infection of the stomach. Abnormalities in the vagal control of acid 
secretion have been postulated in some duodenal ulcer patients.  These 
patients exhibit a dramatic decrease in acid secretion after vagotomy or 
atropine administration. In some patients who have basal acid hypersecretion, 
sham feeding (which activates vagal efferent pathways to the stomach) does 
not cause a further increase in acid output. In these patients the basal acid 
persecretion appears to be driven by increased basal vagal tone that cannot 
be augmented by sham feeding. One report has suggested that the vagus 
nerves may even be larger in duodenal ulcer patients than in control subjects 
without ulcers. 
 
An increased rate of gastric emptying for liquids has been described in 
some patients with duodenal ulcer disease. Conceivably, rapid emptying of 
gastric acid into a vulnerable duodenum might predispose to ulceration. 
Compared with normal individuals, furthermore, patients with active duodenal 
ulcer exhibit a significant decrease in bicarbonate production by the proximal 
duodenum, This phenomenon also might predispose to add-peptic injury in 
the duodenum. Foci of gastric metaplasia are found in the duodenal bulb of 
most patients with duodenal ulcer. Whereas H. pylori can infect  gastric, but 
not intestinal, mucosa, it has been proposed that these islands of infected 
gastric tissue in the duodenal bulb may be especially susceptible to peptic 
ulceration. Some investigators have found a higher prevalence of gastric 
metaplasia in the proximal duodenum of patients with duodenal ulcer disease 
compared with healthy control subjects, whereas others have failed to confirm 
an association between duodenal gastric metaplasia and duodenal ulceration. 
Consequently, the role of duodenal gastric metaplasia in duodenal ulcer 
disease remains unclear. 
An increased acid load in the duodenum may predispose to ulceration 
directly, through the caustic effects of acid on the duodenal epithelium, and 
indirectly, through mechanisms involving H. pylori. The growth of H. pylori is 
inhibited by bile acids that are present in duodenal juice. Acid can precipitate 
bile acids, an effect that might allow H.pylori to proliferate and contribute to 
ulceration in the duodenum. 
 
2.5.2)  ABNORMALITIES ASSOCIATED WITH GASTRIC ULCER 
The gastric antrum normally is lined by a columnar epithelium that does 
not secrete acid, whereas an acid secreting (oxyntic) mucosa with abundant 
parietal cells lines the gastric body and fundus. The large majority of gastric 
ulcers occur in the non-acid-secreting epithelium at or near its junction with 
oxyntic mucosa, a phenomenon suggesting that the non-acid-secreting 
epithelium is inherently more susceptible to peptic ulceration. Long-standing 
gastritis, as occurs in H. pylori infection can cause atrophy of the oxyntic 
mucosa, with the development of intestinal metaplasia and the extension of a 
non-acid-secreting type of epithelium into the proximal stomach.  
Patients who have ulcers located in the proximal stomach usually have 
chronic gastritis and substantial gastric atrophy. Not surprisingly, therefore, 
peptic ulcer disease that involves only the body and fundus of the stomach 
(type I gastric ulceration) has been found to be associated with hyposecretion 
of gastric acid, with a low-normal parietal cell mass and a decreased maximal 
acid output.  Serum levels of pepsinogen II, a protease found in antral, as well 
as oxyntic, mucosa are elevated in patients with type I gastric ulcers.   
 
In contrast, patients who have concomitant ulcers of the gastric body 
and the duodenum (type II gastric ulceration) and patients who have gastric 
ulcers confined to the prepyloric antrum (type III gastric ulceration) have 
abnormalities in gastric acid homeostasis similar to those of patients with 
duodenal ulcer disease, often with  elevated  levels of pepsinogen.  
 
It has been proposed that the reflux of noxious material from the 
duodenum into the stomach may contribute to gastric ulceration in some 
patients. Potentially damaging agents in duodenal juice include bile salts and 
lysolecithin, and increased amounts of these agents have been found in the 
stomachs of patients with gastric ulcers. Decreased pyloric sphincter 
pressures have been found in patients with gastric ulcer, a phenomenon that 
might predispose to duodenogastric reflux.   
 
Antral motility abnormalities and abnormalities in the gastric emptying 
of solids also have been associated with gastric ulceration in some patients.  
The importance of any of these abnormalities in the pathogenesis of peptic 
ulcers remains unclear, and it is known whether the observed motility 
abnormalities are primary defects or secondary effects of gastric ulceration. 
 
Table 2.2 
Reported Abnormalities in Gastric Acid Secretion and Homeostasis in Peptic 
Ulcer Disease. 
Duodenal Ulcer 
Increased: 
Gastric parietal cell mass 
Maximal acid output 
Peak acid output stimulated by meals 
Duration of meal-stimulated acid secretion 
Basal acid output 
Daytime acid output 
Nocturnal acid output 
Fasting serum gastrin levels 
Meal- and GRP-stimulated gastrin levels 
Serum concentrations of pepsinogen I 
Rate of gastric emptying for liquids 
 
Decreased: 
Bicarbonate production by the proximal duodenum 
Gastric Ulcer 
Increased: 
Serum levels of pepsinogen II 
Duodenogastric reflux 
Decreased: 
Gastric parietal cell mass 
Maximal acid output 
 
2.6)  Endoscopic appearance of stomach and duodenum17: 
2.6.1) Esophagus: 
 Esophagus can be inspected in details on either the insertion or 
removal of the endoscope. The upper esophageal sphincter is a high pressure 
zone 2-3cm in length formed by the crico-pharyngeus muscle. The striated, 
skeletal muscle of proximal esophagus transitions gradually to the smooth 
muscle of distal esophagus. The lower esophageal sphincter is tonically 
contracted to prevent reflux of gastric contents and relaxes with swallowing. 
The squamocolumnar junction is junction of white stratified, squamous 
epithelium of esophagus and the salmon colored columnar epithelium of gstric 
cardia. The squamo-columnar junction is normally located within the zone of 
lower esophageal sphincter. The gastro esophageal junction is defined as the 
proximal end of gstric folds. The third landmark of distal esophagus is 
diaphragmatic impressions. 
 
2.6.2) Stomach: 
 
 After entering stomach, the pylorus, antrum, incisura angularis are 
inspected. Retro-flexion is routinely performed in the stomach to allow 
inspection of lesser curvature, cardia, fundus. 
 
 
        
 
 
 
    
 
2.6.3)  Duodenum: 
 Once pylorus is passed, the duodenal bulb is inspected in detail on 
entry. Passing the superior duodenal angle sometimes requires blind 
maneuver and lesions in this area can be difficult to appreciate. The second 
part of duodenum is examined for atleast partial visualization of ampulla of 
vater. 
 
 
2.7 )  EFFECTS OF ASPIRIN ON GASTRO INTESTINAL TRACT6: 
Clinical and epidemiological studies suggests that aspirin produces 
dose related GI toxicity. Meta analysis suggests that the risk of gastro 
intestinal bleeding is not significantly lowered with low dose aspirin (less than 
300mg daily)19. Gastric injury occurs even with doses of 10mg daily. 
Comparative studies of acute gastric mucosal damage by NSAIDs 
consistently associate aspirin with most severe lesions. Gastric mucosal injury 
can occur with even cutaneous application.   
Aspirin related gastro intestinal damage is not limited to the stomach 
and duodenum as these agents also causes injury through the length of GIT. 
 2.7.1)  Pathogenesis of aspirin induced GI toxicity11: 
 The pathophysiology of aspirin induced injury can be grouped into two 
categories.  Those dependent on inhibiton of enzyme COX and those 
independent of COX inhibition16. 
 
a)  Topical damage:     
Topical effects of aspirin is the likely major mechanism responsible for 
acute hemorrhage and erosions. Aspirin is a weak organic acid and soluble at 
gastric pH20. In strongly acid environment of gastric juice (pH<2.5), aspirin is 
non-ionised and freely diffuse into mucosal cell cytoplasm, where they ionize 
at neutral pH and thus become trapped within cells. The high intracellular drug 
causes local toxic effects. These toxic effects lead to abnormal ion flux across 
epithelium, with increase H+ back diffusion, one mechanisms of local effect is 
an uncoupling of oxidative phosphorylation, resulting in mitochondrial energy 
production, a reduction in cellular integrity, and increase in cellular 
permeability21. Another mechanism is an attenuation of phospholipids content 
and surface hydrophobicity of the gastric mucus gel layer22.   
Even 10mg of aspirin significantly reduces the gastric mucosal PGs to 
40 % of basal levels.  10mg, 81mg, 325 mg, aspirin produces gastric injury 
and only 325 mg produces duodenal injury.  325 mg per day aspirin reduces 
duodenal mucosal PGs to 40 %. 
b)  Systemic effects16: 
 COX is the rate limiting enzyme in prostaglandin synthesis is 
systemically inhibited by aspirin and is the major mechanism of GI toxicity. 
Aspirin by acetylation of cyclo oxygenase inhibits this enzyme irreversibly. As 
little as 10mg aspirin suppress gastric prostaglandin by approximately 60% 
and can cause gastric ulcers. After low daily doses of aspirin, prostaglandins 
do not fully recover in stomach approximately 5 to 8days. 
 Although COX inhibition clearly plays an important role in mucosal 
injury, other effects probably contribute to the injury. After aspirin 
administration, gastric acid secretion increases, gastric mucosal flow 
decreases, and duodenal bicarbonate increases and gastrointestinal mucus 
secretion decreases. Among these reduction in gastrointestinal blood flow is 
probably major contributor. 
 
2.8 )  RISK FACTOR FOR ASPIRIN INDUCED GI TOXICITY16: 
 Certain groups of aspirin taking patient appear to be at greater risk of 
development of ulcers and should be given greater consideration for 
strategies to prevent or reduce ulceration. 
 Definite risk factors are prior peptic ulcer disease, advanced age, prior 
NSAID induced gastro intestinal complication, concomitant use of 
glucocorticoids, anti-coagulants, combinations of NSAIDs, comorbid disease, 
ethanol use. 
 Possible risk factors are H.pylori infection, smoking. 
2.8.1)  Old age: 
 Elderly patients are particularly prone to develop aspirin induced GI 
toxicity and unfortunately they are most frequent users of this group of drugs. 
(yeoman, 2001)23.  The elderly patients are deficient in cyto protective 
prostaglandins (PGE2 and PGI2) that increase mucus production and improve 
ulcer healing. Moreover the vascular integrity of the ulcer base is poor. 
Therefore ulcer bleed easily in elderly patients (Dhikav, 2001)24. Elderly 
patients usually have painless gastric ulcerations and NSIAD can mask the 
symptom of pain. Elderly are at the greatest risk for drug induced GI bleeding 
and relative risk at 65-74 year age group is 3-8 times that in general 
population. (Griffin et al, 1991)25. 
 
2.8.2)  Chronic drug intake: 
 Chronic low dose aspirin therapy (150mg/day) for conditions such as 
cardiovascular prophylaxis causes substantial GI toxicity and patients may 
present with iron deficiency anemia, as chronic use of aspirin can cause upto 
2 litres of blood loss over years (Andre26 et al, 1999, yeoman et al 2001). The 
risk of bleeding increases with incremental doses of NSAIDs (Singh, 1999)27. 
 
2.8.3)  Use of gastro-protective agents: 
 Gastro-protective agents are often co-prescribed with low dose aspirin, 
with an aim to reduce the associated GI adverse effects. Co-prescribing rates 
range from 17 to 34% in literature (Rogind, 1997)28. 
 Studies have found significant interactions (P<0.001) between ulcer 
healing drugs and NSAIDs. All the interactions were less than 1.0, indicating 
that the risk of adverse gastro intestinal events associated with taking aspirin 
is low in patients also taking ulcer healing drugs that in patients not taking 
ulcer healing drugs (Hooper et al 2004)29. 
 The most commonly used gastro protective agents include proton 
pump inhibitor, H2 receptor antagonists, antacids, and misoprostol. Although 
these agents have shown to be efficacious to certain extent in prophylaxis and 
treatment of NSAID related events. Parentral PPI are most efficacious of all 
gastro protective drugs. Misoprostol has shown to reduce the serious upper 
GI complications by almost 40%, but is poorly tolerated because of its own 
side effects, mainly diarrhea and abdominal pain. 
 
2.8.4)  Known PUD: 
 Patients with previous history of complicated or un-complicated ulcers 
are reported to have the highest absolute risk (around 38.5%) for UGI 
bleeding (Lucker et al, 1994)30. The VIGOR study (Paulsen et al, 1991)31 
involving over 8000 patients has reported the relative risk of having a GI event 
as 4.0 for patients with prior UGI events. Patients with past history of PUD are 
having highest risk to develop aspirin induced ulcer and bleeding.  
 
2.8.5)  Smoking: 
 Smoking increases acid secretion, reduces prostaglandin and 
bicarbonate production, accelerates gastric emptying and decreases mucosal 
blood flow, all favouring ulcerogenesis. It is suggested atleast in men , chronic 
smoking increases maximal gastric secretion, and therefore could have a role 
in the etiology of duodenal ulcer. Smoking is found to be associated with a 
three fold elevation in the risk of UGI bleed in patients on aspirin compared 
with no smoking (Peura, 2004)32. Ulcer healing with H2 receptor antagonist is 
significantly delayed in smokers compared to non-smokers. Also the relapse 
rate of duodenal ulcer is higher in smokers compared with non-smokers.  
 
2.8.6)  Concomitant use of other gastro toxic drugs: 
 Glucocorticoids lead to atrophy of all epithelial tissues including 
gastrointestinal mucosa. Their rloe in ulcerogenesis is relatively small. 
Hemorrhage in steroid takers is related to duration of therapy and dose. 
Although hemorrhage seems to be the mostimportant complication from 
peptic ulcers in steroid treated patients, gastro duodenal perforation is also a 
well recognized complication attributed to use of cortico steroids leading to 
peritonitis.  Anticoagulants do not cause UGI bleeding per se, but they can 
mask or aggravate hemorrhage from pre-existing lesions (Dalton et al, 
2003)33. Steroids and anticoagulants when combined with low dose aspirin, 
they increase the chance of UGI bleeding many folds. 
 
2.8.7)  Alcoholism: 
 Regular alcohol consumption combined with regular aspirin use is an 
additive risk factor for serious upper GI adverse effects. Regular use of lower 
doses of aspirin increases upper GI risk in those frequently consuming 
alcohol. Among current drinkers, aspirin taken atleast every other day at dose 
of 325mg/day or greater is associated with a seven fold increased risk of UGI 
bleeding when compared with those who do not drink or use low dose aspirin. 
 
2.8.8)  H. pylori infection: 
 Aspirin use and H.pylori infection is regarded as independent risk 
factors for peptic ulcer disease. NSAID users infected with H.pylori have an 
almost two fold increased risk of developing bleeding peptic ulcers compared 
with uninfected NSAID users and low dose aspirin causes more gastric injury 
in H.pylori infected subjects than in uninfected persons. Eradication of H.pylori 
is indicated for patients with identified peptic ulcers, regardless of NSAID use. 
There may be a synergistic injury GI effect between aspirin and H.pylori and 
high risk patients taking aspirin will benefit from H.pylori eradication. 
 
 
2.9 )  ENDOSCOPIC APPEARANCE AND CLINICAL FEATURES OF 
ASPIRIN INDUCED GI TOXICITY: 
 The first endoscopic evidence of adverse effects of aspirin may be 
reported in 1939 by Douthwaite and Lintoff. NSAIDs induced GI damage are 
three main types: 
 1. superficial damage such as mucosal hemorrhage and erosions. 
 2. Endoscopically documented asymptomatic ulcer.  
 3. Symptomatic ulcer causing complication such as GI hemorrhage. 
 
2.9.1)  Superficial lesions11: 
 Sub-epithelial petechiae are hemorrhages and erosions may be seen 
with acute and chronic aspirin ingestion. 
 Within one hour of ingesting a single dose of aspirin multiple sub-
epithelial hemorrhages are seen in stomach especially in fundus. Repeated 
dose of aspirin over a period of 24 hours leads to gastric erosions 
predominantly in the antrum. If aspirin is continued for several days petechiae 
and erosions become less prominent, a process known as gastric adaptation. 
Despite adaptation gastric erosions are found by endoscopy in 30 to 50% of 
patients on chronic NSAIDs. 
 
2.9.2)  Ulcers11: 
 Chronic aspirin ingestion causes gastro duodenal ulceration. Aspirin 
ulcers are usually symptomless unless it is complicated. Early symptoms are 
mild and benign like dyspepsia, nausea, vomiting and anorexia. Pain is 
usually a late feature. When ulcer starts bleeding, hemetemesis and malena 
occurs in 1 to 3% patients (Vikas et al, 2003)34. Elderly patients usually have 
painless gastric ulceration and NSAIDs can mask the symptoms of pain. 
 
 Thus the gastric response to the continuous aspirin injury is to heal and 
to do so at an accelerated rate. This compensatory adaptation is not 
invariable and delayed healing occurs in some patients and there is definite 
association between chronic aspirin ingestion and chronic gastric ulcers.  
 
 
 
 
FEATURES OF ASPIRIN INDUCED GI ulcer: 
1. More than 3mm in size 
2. deep lesions, prone to complications like bleding 
3. perforations  
4. obstructions  
5. multiple erosions (more than 10) 
6. antral in location 
7. absence of H.pylori 
Table 2.3: Effects of Aspirin on upper GI tract: 
Injury Type 
Gastroduodenal 
Lesions 
Frequency 
Acute ( 1-2 weeks) 
Multiply Erythema, 
Superficial Erosions, 
Submucosal 
Haemorrhages, Focal 
Blood Loss 
60  – 100 % 
Chronic ( > 4 weeks) 
Gastric, Antral Erosions, 
Gastric ulcer, Duodenal 
Ulcer and Erosions 
5 - 30 % 
 
2.10 )  Ulcer Complications11: 
Complications of peptic ulcer disease include hemorrhage, perforation, 
penetration, and obstruction. Intractability, previously considered a 
complication of ulcer disease, is exceedingly rare subsequent to the 
development of more effective antiulcer drugs (e.g., H+K+ATPase inhibitors). 
2.10.1) Hemorrhage: 
Hemorrhage, the most common complication of ulcer disease, occurs 
in approximately 15% of patients. Although ulcer hemorrhage may occur at 
any age, it tends to be more common in patients during the sixth decade of 
life and beyond. The higher bleeding rates are in large part due to the 
increased use of NSAIDs. Approximately 10% to 20% of patients bleed from a 
gastric or duodenal ulcer without any antecedent symptoms. Approximately 
one third of patients treated with traditional ulcer therapy (e.g., H2 receptor 
antagonists) have recurrent hemorrhage. Studies suggest that eradication of 
H pylori prevents duodenal ulcer and non-NSAID gastric ulcer recurrences 
and may prevent recurrent hemorrhage. 
2.10.2) Perforation: 
Ulcer-related perforation is less common than hemorrhage but more 
common than obstruction, occurring in approximately 7% of patients with 
peptic ulcer disease. Duodenal ulcers tend to perforate anteriorly, and gastric 
ulcers tend to perforate along the anterior wall of the lesser curvature of the 
stomach. With the increased use of NSAIDs, the incidence of perforation is 
increasing, particularly in women, older than 60 years of age. 
2.10.3) Penetration: 
Penetration is similar pathologically to perforation, except that the ulcer 
crater burrows through the entire wall of the intestine, and instead of leaking 
digestive contents into the peritoneal cavity, the crater bores into an adjacent 
organ. Gastric ulcers most commonly penetrate into the left lobe of the liver, 
while duodenal ulcers penetrate posteriorly into the adjacent pancreas, 
sometimes leading to pancreatitis. Rarely, gastric ulcers may penetrate into 
the colon, resulting in a gastrocolic fistula.  
 2.10.4) Gastric Outlet Obstruction: 
Gastric outlet obstruction, also referred to as gastric retention or pyloric 
stenosis, can result from functional impairment of antral motility due to the 
effects of acute inflammation and edema, or from mechanical obstruction due 
to scarring near the  gastro duodenal junction. The former tends to resolve 
with medical treatment, and the latter usually requires surgical or endoscopic 
(i.e., balloon dilation) intervention. The prevalence of gastric retention is 
approximately 2% in patients with peptic ulcer disease. The symptoms of 
gastric outlet obstruction tend to be insidious and can manifest as 
gastroesophageal reflux, early satiety, weight loss, abdominal pain, and 
vomiting. As the degree of retention increases, the quantity of vomitus also 
increases, often containing food ingested 12 or more hours previously. 
 
2.11)   TREATMENT: 
2.11.1) Treatment of NSAID related dyspepsia: 
a)  H2 blockers: 
 Dyspeptic symptoms are commonly reported by patients taking aspirin. 
In a prospective double blind European study 127 symptomatic individuals 
using NSAIDs without significant abnormalities were randomized to treatment 
with either cimetidine 400mgs twice daily or placebo. 95% patients had upper 
abdominal pain, 60% had nausea, and 75% had heart burn, while only 49% of 
those receiving placebo reported resolution of their symptoms, 72% of those 
receiving cimetidine reported complete symptomatic remission35. 
Vangroenendael36 et al investigated efficacy of ranitidine 150mg twice 
daily in treating NSAIDs related dyspeptic symptoms. Among those without 
endoscopic of any mucosal damage, only 6% and 26% patients treated with 
placebo and ranitidine respectively had complete disappearance of their 
dyspeptic symptoms. 
 
b) Proton pump inhibitors38: 
 In a study by EkStrom37, patients with no or mild dyspepsia and with a 
need for continuous NSAID treatment were randomized to receive either 
20mg omeprazole once daily or placebo. Gastro duodenal ulcers, erosions, 
dyspeptic symptoms were evaluated after 1 and 3 months. The development 
of moderate to severe dyspepsia requiring active treatment, either alone or in 
combination with ulcers or erosions occur in 15.3%  patients treated with 
omeprazole and 35.6% of those who received placebo.   
 A double blind trial comparing omeprazole 20mg once daily and 
ranitidine 150mg twice daily in NSAID users demonstrate that omeprazole 
was significantly more effective than ranitidine in decreasing the incidence of 
dyspepsia.  
 The role of anti-secretory therapy for treatment of upper GI symptoms 
in patients receiving low dose aspirin is less clear. In a double blind trial when 
compared with placebo PPI significantly reduces heart burn but not other 
aspirin associated symptoms. 
2.11.2) TREATMENT OF ACUTE ASPIRIN RELATED GASTRO 
DUODENAL ULCERS16: 
A ) H2 receptor antagonist: 
 Current evidence suggest that conventional doses of H2 receptor 
antagonist effectively heal duodenal ulcer but are ineffective for gastric ulcer. 
In a multi-center study gastric ulcer heal in 63% of those taking NSAID 
compared with 95% of those who had stopped. At 12 weeks 79% of gastric 
ulcers and 92% of duodenal ulcers were healed in group continuing NSAIDs 
whereas GI ulcers healed in those who had stopped taking NSAIDs.  
 
B )  Proton pump inhibitors: 
 Current evidence indicate that PPI is superior to standard dose H2 
receptor antagonist therapy in healing NSAID associated ulcers. In a study 
comparison of 20mg and 40mg omeprazole and ranitidine 150mg (twice 
daily), in patients who continued to take NSAIDs, ulcer healing at 8 weeks 
was found in 805 of patients given omeprazole 20mg daily, in 79% of those 
given omeprazole 40mg daily but in only 63% of those given ranitidine 150mg 
twice daily.  
C )  Misoprostol: 
  Prostaglandin exert their therapeutic effect both by enhancing mucosal 
defensive properties inherent to gastro duodenal mucosa and by inhibiting 
acid secretion, while protective effect is observed with all doses of 
Prostaglandin, acid secretion affected only with higher doses. Misoprostol role 
in NSAID associated ulcer is less studied. One large scale randomized trial 
compare misoprostol 200µg four times daily with omeprazole 20 or 40mg daily 
in patients who continued NSAID treatment. After 8 weeks duodenal ulcers 
healed in 89% patients receiving either doses of omeprazole and 77% of 
those receiving misoprostol. Gastric ulcer healed in 80% of those receiving 
40mg omeprazole, in 87% of those receiving 20mg omeprazole and in 73% of 
those receiving misoprostol. 
 
2.12 )  Prophylaxis12: 
 Individuals who are not at risk for cardio vascular events, do not use 
aspirin and are without risk of GI complication can receive non-selective 
NSAIDs without gastric protection. In those without cardio vascular risks for GI 
complication but with high potential risk for NSAID induced GI toxicity, 
cautious use of selective COX-2 inhibitors or NSAID with gastric protection 
with PPI is order. 
 Patients with cardiovascular risk factors who are on low dose aspirin 
and have low potential for NSAID induced toxicity should be considered for a 
non NSAID agent or use of traditional NSAID in combination with gastric 
protection. Patients with cardiovascular and GI risk who require aspirin must 
be considered for non-NSAID agent. 
MATERIALS AND METHODS: 
4.1 Materials & Methods: 
Place of study:   Thanjavur Medical College Hospital , 
Thanjavur 
Type of study:   Observational study 
Period of study:   December 2007 to November 2008 
Collaborating Department: Medical Gastro Enterology 
Consent:    Informed & Written consent obtained 
 
4.2 Selection of Patients: 
Known CAHD patients already on drugs admitted in medical ward, CAHD 
patients who were registered in cardiology, diabetology, neurology clinics 
and on drugs, periodic follow up were included in this study. 
The study was conducted during December 2007 to November 2008.   
 
4.2.1 Inclusion Criteria:  
1. Patients who were on low dose aspirin ( 150 mg per day ) for at 
least 6 months 
2. Both symptomatic and asymptomatic individuals 
3. Patients on gastroprotective agents and not on gastroprotective 
drugs 
 
4.2.2 Exclusion Criteria: 
The following class of patients were excluded from this study 
1. Patients on less than 6 months of aspirin treatment 
2. Patients with cardiac arrythimas 
3. Patients with severe LV dysfunction 
4. Acute coronary syndrome patients 
5. Poor general condition 
6. Known case of peptic ulcer disease on treatment 
7. Patients who were on high dose aspirin 
 
4.3  Study Methods: 
 Patients who were on low dose aspirin (150 mg per day) for at least 6 
months were selected randomly.  There was no age limit for this study.  
Detailed history was taken and thorough physical examination was made. 
4.3.1 History: 
All patients were asked about  
1. History of dyspeptic symptoms like indigestion, Anorexia, Nausea 
etc. 
2. History of UGI bleed like Hematemesis, Melena. 
3. History of upper abdominal pain. 
4. History of Smoking and Alcoholism. 
5. History of other ulcerogenic drugs like other NSAIDs, 
corticosteroids. 
6. History of Gastro protective agents like H2 receptor antagonists, 
proton pump inhibitors, along with aspirin. 
7. Duration of low dose aspirin. 
8. Past history of upper GI symptoms and peptic ulcer disease. 
9. Treatment history for dyspeptic symptoms. 
4.3.2 Physical Examination: 
1. General condition, anaemia, pulse, blood pressure were recorded. 
2. All systems including abdomen, CVS, respiratory system, nervous 
system were examined and findings noted. 
4.3.3 Consent : 
Informed consent was obtained from all the patients after explaining 
the procedure and risks.  All patients were fasted for a minimum period 
of 8 hours.   
4.3.4 Upper Gastro intestinal endoscopy: 
Prior to the procedure dentures and spectacles were removed.  
Pharynx was anaesthetized with 4 % xylocaine liquid.  No sedation was 
given.  Patients were put on left lateral position.  Examination was 
made out by using flexible “PENTAX VEDIO ENDOSCOPY SYSTEM”  
During this procedure the esophagus, stomach, duodenum were 
visualized for any mucosal abnormalities.  After the procedure the 
instrument was washed in soap and water solution, kept in 2 % 
glutarldehyde solution for a minimum 4 minutes before reuse.  
4.3.5) Limitation of Study : 
1. H.Pylori infection is not excluded 
2. No prior endoscopy examination done before starting aspirin 
NORMAL ENDOSCOPY     GASTRIC ULCER 
                
GASTRIC EROSIONS 
 
   
RESULTS AND OBSERVATION 
 
5.1 SEX DISTRIBUTION 
 
A total of 100 patients were studied. All of them were taking Aspirin for 
secondary prophylaxis for coronary artery heart disease. All Patients were on 
plain Aspirin, 150mg per day. 
Among 100 patients 54 were females and 46 were males. 
 
 
 
5.2 BREAKUP OF PATIENTS WITH REFERENCE TO DURATION OF 
ASPIRIN THERAPY. 
TABLE  5.1  DURATION OF ASPIRIN 
 
DURATION OF ASPIRIN MALE FEMALE TOTAL 
6 months - 12 months 16 17 33 
1 year - 2 years 11 17 28 
> 2 years 19 20 39 
Total 46 54 100 
 
The highest duration of Aspirin intake was 15 years and the lowest 
duration was 6 months. 
 
FIG 5.2 DURATION OF ASPIRIN 
THERAPY
0
5
10
15
20
25
6 months -
12 months
1 year - 2
years
> 2 years
Duration of Aspirin
N
o.
 o
f p
at
ie
nt
s
MALE
FEMALE
 
 
 
5.3   AGE WISE CLASSIFICATION OF PATIENTS: 
  
TABLE  5.2  AGE GROUP DISTRIBUTION OF PATIENTS 
 
AGE GROUP MALE FEMALE TOTAL 
≤ 30 YEARS 0 1 1 
31 - 40 YEARS 5 7 12 
41 - 50 YEARS 8 10 18 
51 - 60 YEARS 13 15 28 
61 - 70 YEARS 17 17 34 
71 - 80 YEARS 2 3 5 
> 80 YEARS 1 1 2 
TOTAL 46 54 100 
 
The highest age of patient participated in study was 85 years and lowest age 
of patient was 25 years. The majority of patients were 34(%) in 61-70 years 
age group. 
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5.4  DISTRIBUTION OF MUCOSAL LESIONS AMONG MALES AND 
FEMALES: 
Among 100 patients studied (52 %) patients had abnormal endoscopy. 
Table  5.3   Distribution of Mucosal lesions among both sexes 
UGI SCOPY Sex 
Group Normal Mucosal Lesions 
TOTAL 
Males 
20 26 46 
Females 28 26 52 
Total 48 52 100 
 
In the current study 46 males were participated, among which 26 
(56.5%) had mucosal lesions. In females 26 (40%) out of 54 had mucosal 
lesions. 
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5.5  PREVALENCE OF SITE OF LESIONS ON ENDOSCOPY: 
 Among 100 patients 52 (%), patients had abnormal mucosal finding on 
upper GI endoscopy. 
    TABLE  5.4  SITE OF LESIONS ON ENDOSCOPY 
 
S. NO SITE OF LESIONS NO. OF PATIENTS PERCENTAGE
1. Stomach 30 57.6% 
2. Duodenum 8 15% 
3. Stomach & Duodenum 11 21% 
4. Esophagus & Stomach 1 1.9% 
5. Esophagus & Duodenum 1 1.9% 
6. 
Esophagus, Stomach & 
Duodenum 
1 1.9% 
   
 
 
 
 30(%) patients had abnormal findings in stomach alone. 8(%) patients had 
abnormal findings duodenum alone and 11(%) patients had abnormal findings 
in both stomach and duodenum. 
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5.6  PREVALENCE OF NATURE OF INDIVIDUAL LESIONS ON 
ENDOSCOPY: 
 Among 100 patients, 25 patients (25%) had lesions at multiple sites. 27 
had mucosal lesions and remaining 48 had normal UGI scopy findings. 
TABLE 5.5 NATURE OF INDIVIDUAL LESIONS ON ENDOSCOPY 
S.NO LESIONS NO. OF PATIENTS PERCENTAGE
1. 
Antral erosions 
23 23% 
2. Pyloric erosions 19 19% 
3. Duodenal erosions 12 12% 
4. Antral ulcer 8 8% 
5. Pyloric ulcer 5 5% 
6. 
Duodenal ulcer 
7 7% 
7. Esophagitis 3 3% 
 
One patient had both antral and pyloric ulcer. 
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5.7 DURATION OF ASPIRIN THERAPY AND UGI SCOPY FINDINGS: 
 
TABLE   5.6 DURATION OF ASPIRIN THERAPY AND UGI SCOPY 
FINDINGS 
 
UGI SCOPY Duration of Aspirin 
Total No-
of Pts Normal Erosions Ulcers Both 
6  - 12 months 33 17 11 2 3 
1 year - 2 years 28 14 8 3 3 
> 2 years 39 17 14 3 5 
Total 100 48 33 8 11 
 
Among 100 patients studied, in 6 months - 1-year group, 17 (51.5 %) had 
normal endoscopy findings, 11 (33.5 %) had erosions, 2 (6 %) had ulcers and 
3 (9 %) had both ulcer and erosions. 
In the 1-2 year duration group, 14 (50 %) had normal endoscopy findings. 8 
(28.5%) patients had erosions, 3 (10.7%) had ulcers and 3 (10.7 %) had both 
ulcer and erosions.  In patients, more than 2 years duration group, 17 (43.5 
%) had no mucosal abnormalities.  14 (35 %) had erosions, 3 (7.6 %) had 
ulcers and 5 (12.8 %) had both erosions, ulcers. 
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5.8 DYSPEPTIC SYMPTOMS AND UGI SCOPY FINDINGS: 
 
Among 100 patients only seventeen (17 %) had various dyspeptic 
symptoms.  Remaining 83 % had no symptoms referable to their upper gastro 
intestinal tract. 
 TABLE  5.7 DYSPEPTIC SYMPTOMS AND UGI SCOPY FINDINGS 
Dyspeptic 
Symptoms 
UGI SCOPY 
 
Total 
No. of 
Patients Normal Erosions Ulcers Both 
Males 7 1 0 5 
(29.5%) 
1 (5.8%) 
Females 10 4 1 (5.8%) 4 
(23.5%) 
1 (5.8%) 
Total 17 5 1 (5.7%) 9 (53%) 2 (12%) 
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Of the 17symptomatic patients, 12(90.5 %) had mucosal abnormalities.  
Among which 9(53 %) had ulcers and 1 (5.8 %) had erosions, and 2 (12 %) 
had both.  Of the 83 asymptomatic patients, 38 (46%) had mucosal 
abnormalities, 45 (54%) had normal findings. 
5.9 NO OF RISK FACTORS & UGI SCOPY FINDINGS: 
Four risk factors viz, smoking, alcoholism, history of prior peptic ulcer 
disease and other ulcerogenic drugs intake were studied.  The following 
findings were noted. 
 
TABLE   5.8 NO OF RISK FACTORS & UGI SCOPY FINDINGS 
 
 
Among zero risk factors, 67% (32) pts had normal findings.  Whereas 3 risk 
factors, only 25 % (1) had normal findings.  Among patients with no risk 
factors, 2 (4.7 %) had ulcers and 14 (29 %) had erosions. 
 
Among patients with one risk factor, 10(33.3%) had ulcers and 
10(33.3%) had erosions. Patients with two risk factors 4(22.2%) had ulcers 
and 9(50%) patients had erosions. 
UGI SCOPY No. of 
Risk 
Factors 
Total No. 
of  
Patients 
Normal Ulcers Erosions 
0 48 32 (67%) 2 (4.7%) 14 (29%) 
1 30 10 (33.35%) 10 (33.35%) 10 (33.35%)
2 18 5 (27.7%) 4 (22.2%) 9 (50%) 
3 4 1 (25%) 3 (75%) 0 
Total 100 48 19 33 
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In this study 17 (%) patients had history of prior PUD out of 17 patients 
only 3 (17.6%) had normal findings and remaining 14 (82.35%) patients had 
mucosal lesions.  Among mucosal lesions 6 (46%) had ulcers.  Among 
patients with no history of PUD 38 (45%) had abnormal findings. 
 
Out of 48 males, 28 (58%) had history of smoking.  Among which 17 
(61%) had mucosal lesions and ulcer in 6 (21.5%) patients. 
 
Among 48 patients participated in the study 21 (43.75 %) were 
alcoholics.  Out of 21, 15 (71.5 %) had mucosal lesions and ulcer in 3 (14 %) 
patients. 
5.10 GASTRO PROTECTIVE AGENTS AND UGI SCOPY FINDINGS: 
 
 
Among 100 patients 84 were on gastro protective Agents. All are taking 
H2 receptors Antagonists. Among 84 patients 39 had  (46.4%) normal 
findings.  The remaining 27 (32%) had erosions and 18 (21 %) had ulcers. 
 
TABLE  5.9  GASTRO PROTECTIVE AGENTS AND UGI SCOPY FINDINGS 
UGI Scopy H/O Gastro 
protective 
drugs 
Total No. of  
Patients Normal Ulcer Erosions 
Male 40 15 13 12 
Female 44 24 5 15 
Total 84 39 (46.4%) 18 (21 %) 27 (32 %) 
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5.11 OLD AGE AND UGI SCOPY FINDINGS: 
41 Patients were above age of  60 years. The UGI scopy findings were 
given below. 
TABLE   5.10  OLD AGE AND UGI SCOPY FINDINGS 
UGI Scopy findings 
> 60 years 
Normal Erosions Ulcer Both 
Total 
Male 9 7 2 2 20 
Female 10 8 1 2 21 
Total 19 15 (36.5 %) 3 (7 %) 4 (9.7%) 41 
 
 
Among 41 patients, 22 (53.6%) had abnormal findings in UGI Scopy.  15 
(36.5%) patients had erosions, 3 (7%) had ulcers and 4 (9.7%) had both 
ulcers and erosions on UGI Scopy examination. 
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59 patients were below 60 years.  Out of which 29 (49%) had 
abnormal endoscopy findings and 15 % had normal endoscopy. 
5.12 HISTORY OF UGI BLEED & ENDOSCOPY FINDINGS: 
Of 100 patients studied, 8 had history of upper Gastro intestinal bleed 
either melena or hematemesis. 
TABLE 5.11 HISTORY OF UGI BLEED & ENDOSCOPY FINDINGS 
H/O UGI 
Bleed 
 
UGI Scopy 
Total 
 
 Normal Erosions Ulcer Both  
Male 1 0 3 1 5 
Female 1 0 1 1 3 
Total 2 0 4 2 8 
 
Among ‘8’ patients 4 (50%) had ulcers, 25 % had both ulcers and erosions. 
 
 
5.13 HISTORY OF OTHER ULCEROGENIC DRUGS:- 
Of 100 patients studied, 12 had history of other ulcerogenic drugs like 
NSAIDs, corticosteroids of which 11(91.6%) had positive findings. 
TABLE   5.12  HISTORY OF OTHER ULCEROGENIC DRUGS 
UGI Scopy 
H/O ulcerogenic drugs Total Normal Ulcer Erosions 
Males 5 0 4 1 
Females 7 1 3 3 
Total 12 1 7 (58.3%) 4 (33.3%) 
 
Among which 7 patients (58.3 %) had ulcers and 4 (33.3 %) had erosions. 
 
Among remaining 88 patients most not taking other ulcerogenic drugs, only 12 
(13.6%) had ulcers. 
DISCUSSION 
The gastro-duodenal toxicity of Aspirin is well known for many 
decades.  Even a single dose of Aspirin can produce gastric erosion.  Even 
though, the reduction of dose of Aspirin from 325 mg daily to 75 mg per day 
reduces the risk of upper gastro intestinal adverse effects, it does not totally 
eliminate the risk. 
 
6.1) Gastro duodenal Mucosal defects by low dose Aspirin:- 
Superficial Lesions:- 
 In the current study out of 100 patients 52 (%) of patients had Mucosal 
defects.  Among which 42 % of patients had gastric erosions, 12 % had 
duodenal erosions, 3% had esophagitis. 
Subepithelial petechiae or hemorrhages and erosions may be seen 
with acute and chronic Aspirin ingestion.  Within 1 hour of single dose of 
Aspirin multiple subepithelial hemorrhages are seen in stomach.  Repeated 
doses of Aspirin over a 24 hours period lead to gastric erosion, predominantly 
in the antrum11. 
In a study by Nema39 et al, showed that, Mucosal defects were found in 
48.4% users of low dose Aspirin. 
In a study by Niv40 et al, showed that, ulcers or erosions in 47.83 % of 
patients. 
In various studies, found that gastric erosions are found at endoscopy 
in 30% to 50% of patients on low dose Aspirin therapy11. 
 
ULCERS:- 
In the present study gastric ulcer was about 13 % and duodenal ulcer 
was 7 %.  Antral Ulcer was common 8 %, of total 20 % of ulcers noted on 
endoscopy. 
Cross sectional studies, in which endoscopy is performed in medical 
patients on chronic Aspirin therapy, the prevalence of gastric ulcers ranged 
from 9 to 31% and the prevalence of duodenal ulcers was 0 to 19%11.  The 
crude prevalence rate of gastric ulcer in chronic Aspirin users is about 13 % 
and that of duodenal ulcer is about 11 %41. 
A study of chronic Aspirin intake of 61 patients with gastric ulcer 
revealed that 32 (52 %) take 15 or more tablets of Aspirin each week 
compared to 6 (10 %) age and sex matches control who took less amounts.  
The regular use of Aspirin was especially associated with ulcers in Antral 
region of stomach.  (mayo clin. Proc.1975 oct: Cameron AJ) 
 
6.2)  Dyspeptic symptoms and endoscopy: 
In the current study 17 % of patients taking Aspirin had severe 
dyspepsia, 55 % of patients with ulcerations were symptomatic and 45 % of 
patients with ulcerations were asymptomatic. 70.5 % of patients had mucosal 
abnormalities in the symptomatic group.  Of the 83 symptomatic patients 46% 
had gastro duodenal mucosal  abnormalities and 54 % had normal endoscopy 
findings. 
Dyspeptic Symptoms are extremely common in patients taking Aspirin.  
In Aspirin myocardial infarction study, severe dyspepsia observed in 24 % of 
patients taking Aspirin and in 15 %  patients given placebo11.   
Dyspepsia is more common in the first few weeks of therapy and tends 
to decline over time regardless of treatment.  Patients wish NSAID-induced 
ulcer complication appears less likely to have symptoms than other ulcer 
patients.  As many as 30 to 40 % of patients with significant mucosal 
ulcerations are asymptomatic43. 
6.3 )  Duration of Aspirin and UGI scopy findings: 
If Aspirin is continued for several days Petechiae or hemorrhages seen 
with acute and chronic low dose Aspirin ingestion.  In this study, patients who 
were on low dose Aspirin for less than a year, 51.5 % had normal UGI scopy 
findings, 33.5 % had erosions and 6 % had ulcers and 9 % had both ulcers 
and erosions.  In the 1-2 year duration group, 50% had normal findings.  
28.5% patients had erosions, 10.7% had ulcers and 10.7% both ulcer and 
erosions.   
In those patients who were taking low dose Aspirin, more than 2 years, 
only 43.5 % had normal UGI scopy, 35 % had erosions, 7.6% had ulcers and 
12.8% had erosions and ulcers. 
In a study of Graham18 et al, showed that if aspirin is continued for 
several days, the petechiae and erosions becoming less prominent.  In a 
study by Soll41 et al, showed that despite adaptation to low dose aspirin, 
gastric erosions are found at endoscopy in 30 to 50 % of patients on chornic 
NSAIDs.  In various controlled prospective studies, conducted in those 
patients on long term NSAIDs patients, indicate that the risk of serious 
NSAIDs induced GI complications appear to be cumulative and linear11. 
This study revealed that as the duration of Aspirin therapy advances, 
the relative frequency of ulcers are increasing.  
6.4 )  Distribution of mucosal lesions among both sexs: 
In the current study 46 % of patients were males, among which 56.5 % 
had mucosal lesions.  In females 40 %, out of 54 % of patients had mucosal 
lesions. 
In a study by Gabriel44 et al, found an equivalent risk between the sexs.  
The higher prevalence of mucosal lesions among males in the current study 
may be due to more risk factors. 
6.5 )  Risk factors for aspirin induced GI lesions: 
Certain group of aspirin taking patients appear to be greater risk for 
development of aspirin induced ulcer complications. 
In this study 48 % patients had no risk  factors and among which 67 % 
of patients had normal UGI scopy findings.  Among patients with one risk 
factor 33.3 % had normal UGI scopy.  Among patients with two risk factors 
27.7 % had normal UGI scopy and patients with 3 risk factors, only 25 % had 
normal scopy findings.   
Studies by Wolfe11 et al, Laine45 et al, Hoachain46 et al, showed that 
multiple factors including increasing age, history of ulcer or GI complications, 
concomitant anticoagulation therapy, concomitant corticosteroid use  and high 
dose NSAIDs use.  It also revealed that, patients with more numbers of risk 
factor had more gastric mucosal lesions especially ulcers. 
6.6 )  Alcoholism and Ulcers: 
In the current study, 48 males were participated, among which 43.75 % 
were alcoholics.  Out of which 71.5 % had mucosal lesions and 14 % had 
ulcers. 
In a study by Kaufman47 et al, revealed that among current drinkers 
aspirin taken  at least every other day 325mg / day is associated with a seven 
fold increased risk of upper GI events when compared with those who do not 
drink. 
6.7 )  History of prior peptic ulcer disease and UGI scopy findings: 
In this study 17%  of patients  had history of prior PUD.  Out of which 
82.35 % had mucosal lesions and 17.65 % had normal UGI scopy findings.  
Among patients with no history of prior PUD 45 % abnormal mucosal lesions. 
 
In various studies, concluded that the most important risk factor for 
aspirin induced GI complications is history of prior PUD, which increase the 
risk of Aspirin induced GI events by two fold to four fold16. 
 
6.8 )  Old age and UGI socpy findings: 
In the present study, 41 % of patients were above age of 60 years.  
Among which 53.6% had abnormal findings in UGI scopy.  36.5 % had 
erosions and 7 % had ulcers, 9.7 % had both ulcers and erosions.  In less 
than 60 years age group patients, only 49 % had abnormal findings. 
In a study by Gabriel44 et al, showed that the relative risk is greater 
than 5 in aspirin users older than 60 years age but less than 2 in younger 
patients.   8 Randomized , placebo controlled studies by Sibilia48 et al, 
showed that erosions, particularly gastric erosions are more frequent in 
elderly than younger patients. 
In the prospective aspirin myocardial infarction study, there was linear 
relation in the aspirin-treated group between ulcer complications and the age 
of patients11.  In a study by Lanza49 et al, showed that the likely hood of 
serious events appears to increase in liner fashion, with no significant 
increase in ulcer bleeding reported among patients aged 35 – 49 years and 2-
9 fold increase in patients aged 50 to 64 years. 
 
6.9 )  History of other ulcerogenic drugs and UGI scopy findings : 
Of 100  patients studied, 12 % had history of other ulcerogenic drugs 
like NSAIDs, conticosteroids.  Of which 91.6% had positive findings and  
58.3% had ulcers. 
Among patients with no history of other ulcerogenic drugs, 13.6% had ulcers. 
In various studies ( by silverstein et al, Stornch et al, Laine et al,)11 & 16 
revealed that low dose aspirin with concurrent NSAIDs, markedly increases 
the risk of Aspirin induced ulcers by two fold to six fold above the risks 
associated  with aspirin alone. 
 
6.10 )  History of UGI bleed and endoscopy findings: 
In the current study 8 % of patients had history of UGI bleed.  Among 
which 50% had ulcers, 25 % had both ulcers and erosions.   
In a study by Lans50 et al, showed that peptic ulcers accounted for 42 
% of UGI bleed, in patients on Aspirin.  In a meta analysis  of 24 randomised 
controlled trials by Sheena51 et al, showed that at doses below 163 mg/day, 
GI bleed occurred in 2-3% of patients taking Aspirin. 
In a review by Sibilia48 et al, showed that a non-significant increase in 
esophageal, gastric and duodenal ulcers during treatment with low dose 
aspirin, but a significant increase in bleeding ulcers. 
 
6.11 )  Gastro protective agents and UGI scopy findings: 
In the current study, 8.4 % of patients were on gastro protective 
agents.  All are taking H2- receptor antagonists.  Among them, 46.4% had 
normal findings, 32% had erosions and 21 % had ulcers. 
When aspirin is continued, ulcer healing appear to be delayed and is 
largely dependent on the initial ulcer diameter.    
In a randomised study by Lana Caster- Smith MS52 et al, 190 patients 
with endosopically confirmed gastro duodenal ulcers, patients were assigned 
to continue, or discontinue Aspirin therapy.  All patients were treated with 
Ranitidine 150 mg BD.  After 8 weeks, healing of gastric ulcers was observed 
in only 63% of those on drugs, compared with 95 % of those who stopped 
them. 
For duodenal ulcers, the corresponding 8 week healing rates were 84 
% in the group continuing Aspirin and 100 % in those who discontinued them. 
It appears that although healing of large gastric ulcers is delayed when 
Aspirin use is continued, healing may be achieved provided H2 RA therapy is 
continued for an extended period of time.  However with advent of more 
potent anti- secretory agents such as PPIS, the use of H2RA in the healing of 
Aspirin-related ulcers is no longer recommended as first line therapy38. 
CONCLUSION 
 
1) This study on endoscopic findings in low dose aspirin therapy shows, 
52 % of patients had abnormal mucosal findings, whereas 48% of 
patients had normal study.  So the incidence of abnormal endoscopic 
findings is almost  the same as normal endoscopy findings. 
 
2) Various Upper GI lesions noted in this study as follows:- 
Antral erosions 25 % 
Pyloric erosions 19 % 
Duodenal erosions 12 % 
Antral ulcer 8 % 
Pyloric ulcer 5 % 
Duodenal ulcer 7 % 
Esophagitis 3 % 
 
Antral erosions is the commonest abnormality noted in this study.  Antral 
ulcer is commonest among ulcers.  Prevalence of mucosal lesion is lowest 
in esophagus (3 %). 
 
3) The mucosal lesions induced by low dose aspirin is more in stomach 
rather than duodenum. 
 
4) H2 receptor is not a safe drug to prevent the upper GI lesions during 
low dose aspirin therapy. 
 
5) 70.5 % of Dyspeptic patients had abnormal findings in gastro duodenal 
mucosa.  This shows dyspeptic symptoms correlate well with 
endoscopic findings. 
 
6) If the duration of low dose aspirin consumption increases, likelihood of 
having ulcers is more. 
 
7) If the patient has more risk factors, more chances of having mucosal 
lesions. 
 
8) Old age is associated with more mucosal lesions. 
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PROFORMA 
 
UPPER GI ENDOSCOPY FINDINGS IN LOW DOSE ASPIRIN CONSUMERS: 
 
Patient’s Name  : 
Age / Sex   : 
O.P/I.P No.   : 
Diagnosis   : 
Dose of Aspirin  : 
Duration of Aspirin  : 
H/O prior PUD  : 
H/O smoking   : 
H/O Alcoholism  : 
H/O other ulcerogenic drugs : 
H/O Dyspepsia  : 
H/O Upper Abdominal Pain : 
H/O Gastro protective drugs : 
H/O UGI Bleed  : 
 
Examination: 
Anemia   : 
Pulse    : 
BP    : 
Abdomen   : 
Cardiovascular system : 
Respiratory system  : 
Nervous system  : 
 
UGI Scopy findings: 
Date    : 
Esophagus   : 
Stomach   : 
Duodenum   : 
 
 
 
S. Patient’s Name Age O.P / Duration H/O Gastro H/O H/O 
No. &  I.P  of H/O H/O H/O H/O Other Protective Dyspeptic UGI
Sex No. the Aspirin  Prior  Smoking  Alcoholism Ulcerogenic  Drugs Symptoms  Bleed Esophagus Stomach
PUD drugs
1 PALANIYANDI 45 / M 995175 5 YEARS - + + - H2A + N N
2 SARASWATHI 65 / F 1002890 2 YEARS - - - - - - - N ANTRAL EROSIONS
3 MUNIAMMAL 61 / F 2201/07 7 YEARS - - - - - - - N ANTRAL EROSIONS
4 RAJARAJAN 61 / M 1004508 15 YEARS - - - - - - - N PYLORIC EROSIONS
5 RANI 37 / F 1004724 6 MONTHS - - - - - - - N N
6 RAJAM 50 / F 1004683 6 MONTHS - - - - - + - N N
7 UDHYA SURIYAN 45 / M 3531/08 6 MONTHS - + + + H2A + - N ANTRAL ULCER & EROSIONS
8 LAKSHMI 60 / F 4362/03 5 YEARS - - - - H2A - - N N
9 LATHA 38 / F 992170 8 MONTHS + - - - H2A + - ESOPHAGITIS ANTRAL EROSIONS
10 KALIYAMMAL 65 / F 1003259 8 MONTHS + - - - H2A - + N ANTRAL ULCER
11 GRACEMARY 55 / F 1004035 10 YEARS - - - - H2A - - N N
12 SURESH 30 / M 1003191 7 MONTHS - + + - H2A + - N N
13 THANGARAJ 50 / M 1003861 5 YEARS - + - + H2A - - N N
14 SIRONMARY 45 / F 3918/08 9 MONTHS + - - - H2A - - N N
15 SARATHAMBAL 94 / F 1003708 3 YEARS - - - - H2A - - N N
16 CHKKARAVARTHY 62 / M 1004166 3 YEARS + + - + H2A + + N ANTRAL & PYLORIC EROSIONS
17 KARUPAIYAN 50 / M 1004155 1.6 YEARS - + + - H2A - - N PYLORIC EROSIONS
18 SUNDARAMBAL 40 / F 1005579 10 YEARS - - - - H2A - - N N
19 JEGADAMBAL 65 / F 1005393 12 YEARS - - - - H2A - - N PYLORIC & ANTRAL EROSINS
20 SUNDARAVALLI 60 / F 1005609 1.8 YEARS - - - - H2A - - N N
21 PUSPHAM 38 / F 1005050 1.6 YEARS - - - - H2A - - N N
22 THIYAGARAJ 78 / M 1005531 5 YEARS - - + - H2A - - N N
23 RANGABHASYAM 62 / M 1005228 4 YEARS - - - - H2A + + N N
24 NAGARAJAN 70 / M 100564 2 YEARS - + - - H2A - - N N
25 GOVINDHARAJ 50 / M 1005991 5 YEARS - - + + H2A - - N ANTRAL EROSIONS
26 UMARANI 53 / F 1006212 6 MONTHS - - - - H2A - - N N
27 LAKSHMI 25 / F 1006148 6 YEARS - - - - H2A - - N N
28 MANORANJTHAM 65 / F 1008306 5 YEARS - - - - H2A - - N N
UPPER  G I ENDOSCOPY FINDINGS IN LOW DOSE ASPIRIN CONSUMERS:
MASTER CHART
RISK FACTORS UGI SCOPY
29 MUTHAIYAN 70 / M 1008058 5 YEARS - + + - H2A - + N N
30 SWAMINATHAN 65 / M 1008346  6 MONTHS + + + - H2A + - N ANTRALEROSIONS & ULCER
31 MANORANJITHAM 78 / F 1008441 2 YEARS - - - + H2A - - N PYLORIC EROSIONS & ANTRAL ULCER
32 BALASAMY 60 / M 1003690 1.2 YEARS - + - - H2A - - N N
33 LALITHA 50 / F 1004074 1.6 YEARS - - - - H2A - - N PYLORIC EROSIONS
34 PATTU 65 / F 1004341 3 YEARS - - - - H2A + - N N
35 GOVINDHARAJ 60 / M 1004847 8 MONTHS - + + - H2A - - N N
36 GLIAMARY 43 / F 1003650 1.3 YEARS + - - - H2A - - N ANTRAL EROSIONS
37 RAMU 58 / M 1009075 5 YEARS - - + - H2A - - N PYLORIC EROSIONS
38 SAROJA 66 / F 1009127 6 YEARS - - - - - - - N N
39 MUNIAMMAL 42 / F 5923/07 1.6 YEARS - - - + H2A + - N PYLORIC ULCER
40 KRISHNAMMAL 85 / F 989742 10 YEARS - - - - H2A - - ESOPHAGITIS N
41 VEERAMMAL 65 / F 991265 1.6 YEARS - - - - - - - N ANTRAL EROSIONS
42 MAHALINGAM 85 / M 1009737 3 YEARS - - - - H2A - - N N
43 RAJAGOPAL 65 / M 1009841 6 MONTHS - + + - H2A - - N ANTRAL EROSIONS
44 NAVAMANIAMMAL 70 / F 991431 1.2 YEARS - - - - H2A - - N N
45 VIAMALA 50 / F 993175 2 YEARS + - - - H2A - - N ANTRAL & PYLORIC EROSIONS
46 KALIYASUNDARAM 70 / M 991805 7 MONTHS - + - - H2A - - N N
47 DHABILAK BEGUM 35 / F 992296 8 MONTHS - - - + H2A - - N N
48 MARUTHAMBAL 60 / F 993519 1 YEAR - - - - H2A - - N ANTRAL EROSIONS
49 ANANTHAKUMAR 45 / M 1009817 3 YEARS - + + - H2A - - N N
50 RAJENDRAN 63 / M 1010197 2 YEARS - + - - H2A - - N ANTRAL EROSIONS & PYLORIC ULCER
51 PATTU 70 / F 994269 2.6 YEARS + - - - H2A - + N N
52 RAJAMMAL 65 / F 994183 6 MONTHS - - - - H2A - - N N
53 VIJIYALAKSHMI 55 / F 999557 8 MONTHS - - - + H2A - - N PYLORIC & ANTRAL EROSINS
54 JOTHIAMMAL 50 / F 996068 1.2 YEARS - - - - - - - N N
55 SRINIVASAN 69 / M 1009767 3 YEARS - + + - H2A - - N N
56 MARAGATHAM 46 / F 996929 2 YEARS - - - - H2A - - N N
57 DHINAKARAN 39 / M 1009780 6 MONTHS + + - - H2A - - N PYLORIC ULCER & EROSIONS
58 SUSHILA 45 / F 1002876 6 MONTHS - - - - H2A - - N ANTRAL ULCER
59 ANJAMMAL 60 / F 992975 2 YEARS + - - - H2A - - N PYLORIC EROSIONS
60 DHANABAKKIAM 58 / F 993871 8 YEARS - - - - H2A - - N N
61 VADUGAMBAL 52 / F 993901 1.10 YEARS - - - - H2A + - N N
62 ANJAMMAL 55 / F 995699 3 YEARS - - - - H2A + - N N
63 AYYASAMY 67 / M 1009731 8 MONTHS - + + - - - - N N
64 RAMU 60 / M 1009800 6 MONTHS - + - - H2A - - N N
65 JEYALAKSHMI 80 / F 996132 5 YEARS - - + - H2A - - N PYLORIC EROSIONS
66 CHANDRA 50 / F 996816 8 MONTHS - - - + H2A - - N ANTRAL EROSIONS
67 ANJALAI 60 / F 998290 1.4 YEARS - - - - H2A - - N N
68 VASANTHA 40 / F 998492 9 MONTHS + - - - H2A - - N PYLORIC EROIONS
69 DURAIRAJ 70 / M 1009481 10 YEARS - + - - H2A - - N ANTRAL EROSIONS & ULCER
70 GOVINDHARAJ 70 / M 1008334 2 YEARS + + - - H2A - - ESOPHAGITIS ANTRAL EROSIONS 
71 PANCHAVARNAM 60 / F 999180 2.6 YEARS - - - - - - - N N
72 SARATHAMBAL 70 / F 999175 3 YEARS - - - - H2A - - N PYLORIC EROSIONS
73 SIVAGAMI 65 / F 1001080 6 MONTHS - - - - H2A - - N N
74 SWAMINATHAN 51 / M 7530/07 1.3 YEARS + - - - H2A - - N N
75 MANICKKAM 54 / M 3484 6 MONTHS - + + - H2A + - N PYLORIC EROSIONS
76 PUSPHAM 70 / F 1002306 3 YEARS + - - - H2A + - N PYLORIC ULCER & EROSIONS
77 PAPATHI 65 / F 1003126 8 MONTHS - - - + H2A - - N N
78 MARIAMMAL 70 / F 1005958 5 YEARS - - - - H2A - - N N
79 AJIJA BEEVI 70 / F 5689/08 1.3 YEARS - - - - H2A - - N N
80 SARAVANAN 38 / M 1010804 2.3 YEARS + + - - H2A - - N ANTRAL EROSIONS
81 PALANIVEL 60 / M 1010878 8 MONTHS - - - - H2A - - N N
82 SAGAYAMARY 51 / F 1011792 6 MONTHS - - - - H2A - - N N
83 MURUGAIYAN 75 / M 9648107 1.6 YEARS - - + - - - - N N
84 ANBU 40 / M 1011312 8 MONTHS - + + - H2A - - N N
85 AKBAR HUSSAIN 61 / M 1010392 11 MONTHS - - - - - - - N N
86 BHADMAVATHI 40 / F 4766108 6 MONTHS - - - - H2A + - N ANTRAL EROSIONS
87 CHANDRA 57 / F 1644/06 2.6 YEARS - - - - - + + N ANTRAL ULCER & EROSIONS
88 JULEKHAKHAN 56 / F 8433107 1.2 YEARS - - - + H2A + - N N
89 KANNAN 60 / M 789/06 2.6 YEARS + - - - H2A - - N PYLORIC EROSIONS
90 THANGAIYAN 54 / M 990495 1.6 YEARS - + + - H2A - - N N
91 RAJU 50 / M 1002628 8 MONTHS - - - - - - - N N
92 SIVARAMAN 60 / M 1001503 4.7 YEARS - - - - H2A - - N N
93 RENGASAMY 62 / M 1003110 2.2 YEARS - - - - H2A - - N PYLORIC EROSIONS
94 SARAVANAN 35 / M 1003217 9 MONTHS - + + - H2A - - N ANTRAL EROSIONS
95 MANI 60 / M 1002897 3 YEARS - + - - H2A - + N PYLORIC ULCER
96 MITHEEN 60 / M 991911 8 MONTHS + + + - H2A + - N PYLORIC EROSIONS
97 VEMBAIYAN 60 / M 993899 2.8 YEARS - - - - H2A - - N N
98 MURUGAIYAN 60 / M 904701 1.7 YEARS - - - + H2A - - N ANTRAL ULCER
99 ANANDHAN 65 / M 994921 3 YEARS - - - - H2A - - N N
100 GOVINDHARAJ 50 / M 995649 1.4 YEARS - - - - H2A - - N ANTRAL EROSIONS
       N- NORMAL ,                + - PRESENT ,            - - ABSENT ,           H2A - H2 ANTAGONIST
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